The correlation of temporal changes of neutrophil-lymphocyte ratio with seizure severity and the following seizure tendency in patients with epilepsy

Hanli Li1†, Yujing Yang1†, Mingwei Hu1†, Xiaoyan Cao1†, Chuhan Ding1, Qibing Sun1, Ran Li1, Ruonan Liu2, Xihai Xu2* and Yu Wang1*†

1Department of Neurology, Epilepsy and Headache Group, The First Affiliated Hospital of Anhui Medical University, Hefei, China, 2Department of Health Management Center, The First Affiliated Hospital of Anhui Medical University, Hefei, China

Background: Changes in the neutrophil-lymphocyte ratio (NLR) has been reported to be associated with epilepsy. Here we aim to investigate the correlation of temporal changes of NLR level with seizure severity and the follow-up seizure attacks in patients with epilepsy (PWE).

Methods: We performed a retrospective analysis of the laboratory data including leukocyte count and NLR within 24 h of acute seizure and during the follow-up period of 5–14 days after acute seizure (NLR1, NLR2, respectively) in 115 PWE, and 98 healthy individuals were included as controls in this study. The correlation of laboratory data with seizure types, etiology of epilepsy, anti-seizure drugs (ASDs), seizure severity, and the follow-up seizure attacks in PWE was studied.

Results: Leukocyte count ($P < 0.001$) and NLR level ($P < 0.001$) were found significantly different between PWE and controls. On the other hand, a multivariable logistic regression analysis showed that NLR1 level (OR = 2.992, $P = 0.001$) and admission leukocyte (OR = 2.307, $P = 0.002$) were both independently associated with acute epileptic seizures. Especially, higher NLR1 level was significantly associated with status epilepticus ($P = 0.013$) and recurrent seizures after admission ($P < 0.001$). Furthermore, the multivariable logistic regression analysis indicated that higher NLR1 was a predictor for the tendency of the following recurrent seizure attacks (OR = 1.144, $P = 0.002$). NLR2 was inversely correlated with ASDs taken ($P = 0.011$). Levels of NLR1 ($r = 0.441, P < 0.001$) and NLR2 ($r = 0.241, P = 0.009$) were both positively correlated with seizure severity.

Conclusions: Seizures were correlated with the alterations of systemic inflammation reflected by leukocyte and NLR. NLR1 and admission leukocyte were both independently associated with acute epileptic seizures. Higher NLR1 was associated with status epilepticus and independently predicted the...
Introduction

As a chronic neurological disorder, epilepsy affects over 70 million people in the world and imposes a substantial burden on individuals and society (1). It has been found that seizures can significantly impair the quality of human life and this influence depends on the severity of seizures (2). People with epilepsy visit the emergency room more frequently than the general population, with 22% of children and 13% of adults with epilepsy visiting the emergency room each year (3). Acute seizures have long been known to cause higher early mortality in patients with epilepsy (PWE) (4), though a recent report on a more direct and absolute measure of life expectancy has shown that life expectancy is reduced in symptomatic epilepsies, but, prolonged in other subgroups of epilepsies (5). On the other hand, mortality-related sudden unexpected death in epilepsy (SUDEP) can occur immediately during or after a tonic-clonic seizure (6) and it has been shown to be related to the severity of epilepsy (7, 8). Hence, it is necessary to identify possible biomarkers to help predict or mark the development of epilepsy as well as the associated seizure severity for early intervention.

Multiple evidences have indicated the correlation between neuroinflammation and epilepsy. Epileptic seizures provoke neuroinflammation which reciprocally facilitates epileptic seizures (9–12). For example, seizures trigger an increase in pro-inflammatory mediators including COX-2, IL-1β, IL-6, HMGB1, TNF-α and chemokines, which in turn exacerbate epilepsy development (13). Furthermore, neuroinflammation has been shown to contribute to the onset and recurrence of epileptic seizures by lowering its threshold (14). The association of systemic inflammation with epilepsy has also been established (15, 16). Additionally, anti-inflammatory therapy has seizure-suppressing effect (17), such as glucocorticosteroids, an inflammation inhibitor, has significant effect in treating epilepsy of non-inflammatory etiology (18).

Neutrophil–lymphocyte ratio (NLR), which is calculated directly from the complete blood cell count, has been established as a biomarker for systemic inflammation. In previous studies, a relationship between increased level of NLR and central nervous system (CNS) diseases, such as neurodegenerative and cerebrovascular diseases, has been established (19–22). The association of NLR level with epilepsy has been investigated in several studies (23, 24). However, it is still unclear of the relationship of NLR with either the severity of acute seizure or the recurrence of follow-up seizures in PWE. In this study, the association of NLR with the acute seizure severity and the follow-up seizure attacks in PWE will be studied. Besides, the association of temporal changes of NLR level after an acute seizure attack with seizure type, etiology of epilepsy, anti-seizure drugs (ASDs) and status epilepticus (SE) will also be investigated in this study.

Materials and methods

Study population

We conducted a retrospective cohort study of PWE in the Department of Neurology, The First Affiliated Hospital of Anhui Medical University from November 2017 to March 2022. This retrospective study was approved by the institutional review board. All PWE were diagnosed according to the International League Against Epilepsy (ILAE) guideline (25). The inclusion and exclusion criteria were shown in Table 1. The inclusion criteria for PWE were: ≥ 16 years in age, admission for an acute epileptic seizure and availability of a complete blood count with laboratory data at admission (within 24 h of acute seizure) and during the follow-up period of 5–14 days after admission. We excluded patients who had a concurrent or recent infection tendency of the following epileptic seizures. NLR2 was significantly associated with ASDs taken. Besides, NLR may be used as a biomarker for seizure severity.

| Inclusion criteria | Exclusion criteria |
|--------------------|-------------------|
| Diagnosis of epilepsy according to the ILAE criteria; | A concurrent or recent infection; |
| Age ≥ 16 years; | An acute or subacute traumatic brain injury; |
| Admission for an acute epileptic seizure; | An acute or subacute of cerebrovascular disease; |
| Availability of a complete blood count with differential laboratory data at admission and during follow-up period of 5–14 days after admission. | A recent myocardial infarction; |
| | Hematological disease; |
| | Malignancy; |
| | Severe liver or kidney disease; |
| | Pregnant; |
| | Receiving immunomodulatory therapy. |

PWE, patients with epilepsy.
which was active within 2 weeks before admission including local and systemic infection, such as lung infection, urinary tract infection, and endocarditis. At the same time, acute or subacute traumatic brain injury, acute or subacute cerebrovascular disease within 2 weeks, recent myocardial infarction within 3 months before the study, hematologic diseases, malignancy, and severe liver and kidney diseases were excluded. In addition, patients who were pregnant or receiving immunomodulatory therapy were not included. SE was defined as a seizure lasting ≥30 min, generalized convulsive SE was defined as (1) seizure duration ≥5 min or two or (2) more discrete seizures with incomplete recovery of consciousness between seizures (25). Epilepsy diagnosed for the first time with first prescription of ASDs on admission was defined as newly diagnosed epilepsy (26). Finally, 115 PWE were included in the study.

A total of 500 healthy individuals were selected based on previous health examination records, among which 98 cases were randomly selected as controls. The control group and PWE group were matched in gender and age.

Data collection and outcome measures

The laboratory data and image information of all patients at admission were retrospectively collected based on the hospital electronic medical record system. Complete blood cell count and leukocyte classification laboratory data were recorded within 24 h of the acute seizure and during a follow-up period of 5–14 days after admission. Blood pressure, C-reactive protein (CRP), liver and kidney function, blood glucose, electrolytes and lipids, electroencephalogram (EEG) and brain magnetic resonance imaging (MRI) were measured in all patients. All brain MRI data were interpreted by experienced neurologists and neuroradiologists who were unaware of the clinical factors of the patients. Duration of illness, epileptic seizure types, the follow-up seizure attacks after admission and the use of ASDs before admission were also collected for all patients. The National Hospital Seizure Severity Scale (NHSS3) which contains seven seizure-related factors on a score of 1 to 27 was used to assess the severity of epilepsy (27, 28).

In this study, we reviewed baseline laboratory and clinical factors in patients and healthy controls, including gender, age, systolic blood pressure (SBP), diastolic blood pressure (DBP), albumin, triglyceride (TG) and total cholesterol (TC). A complete blood cell count including total leukocyte count, neutrophil count, and lymphocyte count was collected within 24 h of the acute seizure and during a follow-up period of 5–14 days after admission. As there was no follow-up period in the control group, single laboratory data was included in this study. NLR was calculated by dividing the absolute number of neutrophil by the absolute number of lymphocyte at each time point. NLR at admission within 24 h of an acute seizure was defined as NLR1 and NLR during the follow-up period of 5–14 days after admission defined as NLR2. If more than one laboratory data was available for the NLR, the maximum value was recorded.

Statistical analyses

All the data were statistically analyzed with SPSS 25.0 statistical software. Continuous variables, if normally distributed, were presented as means ± standard deviation. For non-normally distributed variables, the median of the interquartile range was used for analysis. The independent sample t-test and Pearson’s correlation were used for comparison of means, the chi-square test was performed for comparison of categorical variables. Mann Whitney U test and Spearman’s correlation were used for non-normally distributed data. Univariate and multivariate logistic regression analyses were used to exclude confounding factors and predict risk factors. A receiver operating characteristic (ROC) curve and the area under the curve (AUC) were used to determine the sensitivity and specificity of the NLR diagnostic test. In all analyses, P <0.05 was defined as statistically significant.

| TABLE 2 Demographic and laboratory characteristics of patients with epilepsy and controls. |
|---------------------------------------------------------------|
| **Epilepsy** | **Control** | **P value** |
| -------------- | ----------- | ----------- |
| Gender(M / F)  | 68/47      | 53/45      | 0.540      |
| Age (year)     | 45 ± 17(16–81) | 45 ± 15(18–77) | 0.969 |
| SBP (mmHg)     | 126.17 ± 21.56 | 124.26 ± 14.03 | 0.910 |
| DBP (mmHg)     | 77.78 ± 14.41 | 74.73 ± 9.36 | 0.134 |
| Albumin (g/L)  | 40.80(35.50–44.00) | 45.85(44.35–47.93) | <0.001 |
| TG (mmol/L)    | 1.04(0.79–1.47) | 1.27(0.87–1.81) | 0.084 |
| TC (mmol/L)    | 3.97(3.52–4.79) | 4.79(4.15–5.35) | <0.001 |
| Leukocyte1(*10^9/L) | 9.25(6.81–13.10) | 5.76(4.81–7.04) | <0.001 |
| Neutrophil1(*10^9/L) | 6.86(4.23–9.93) | 3.18(2.45–4.00) | <0.001 |
| Lymphocyte1(*10^9/L) | 1.47(0.96–2.04) | 2.02(1.66–2.49) | <0.001 |
| NLR1           | 4.41(2.42–8.65) | 1.53(1.23–2.00) | <0.001 |
| Neutrophil2(*10^9/L) | 6.50(5.31–7.71) | 5.76(4.81–7.04) | <0.001 |
| Lymphocyte2(*10^9/L) | 4.11(2.86–5.07) | 3.18(2.45–4.00) | <0.001 |
| NLR2           | 1.54(1.21–1.99) | 2.02(1.66–2.49) | <0.001 |
| Disease duration (year) | 3.89 ± 8.22(0.40) | – | – |
| NHSS3 score    | 11.15 ± 3.75(1–19) | – | – |

M, male; F, female; SBP, systolic blood pressure; DBP, diastolic blood pressure; TG, triglyceride; TC, total cholesterol; Leukocyte1, admission leukocyte count; Neutrophil1, admission neutrophil count; Lymphocyte1, admission lymphocyte count; Leukocyte2, follow-up leukocyte count; Neutrophil2, follow-up neutrophil count; Lymphocyte2, follow-up lymphocyte count; NLR, neutrophil–lymphocyte ratio.
Results

The main demographic and laboratory characteristics of the PWE group and healthy controls

A total of 115 patients (mean age 45 ± 17 years, age range 16–81 years, 67 male, 48 female) and 98 healthy controls (mean age 45 ± 15 years, age range 18–77 years, 53 male, 45 female) were included in this study. The main demographic and laboratory characteristics of the patients and healthy controls were presented in Table 2. Compared with healthy controls, admission leukocyte count (P < 0.001), follow-up leukocyte count (P < 0.001), admission neutrophil count (P < 0.001), follow-up neutrophil count (P < 0.001), levels of NLR1 (P < 0.001), NLR2 (P < 0.001) and TC (P < 0.001) were all significantly increased, nevertheless, admission lymphocyte count (P < 0.001), follow-up lymphocyte count (P < 0.001) and albumin level (P < 0.001) significantly decreased in PWE group. No significant differences in gender, age, SBP, DBP and TG were found between two groups.

Temporal changes of neutrophil-lymphocyte laboratory data for PWE

In PWE group, the numbers of leukocyte (P < 0.001) and absolute neutrophil (P < 0.001) and the level of NLR (P < 0.001)

TABLE 3 Univariate and multivariate logistic analyses of parameters associated with acute epileptic seizure in patients with epilepsy.

| Parameters          | Crude OR (95% CI) | P value | Adjusted OR (95% CI) | P value |
|---------------------|-------------------|---------|----------------------|---------|
| Leukocyte1          | 0.559 (0.466–0.671) | <0.001  | 2.307 (1.356–3.923)  | 0.002   |
| NLR1                | 0.244 (0.153–0.388) | <0.001  | 2.992 (1.579–5.669)  | 0.001   |
| Leukocyte2          | 0.772 (0.653–0.913) | 0.002   | 0.652 (0.399–1.064)  | 0.087   |
| NLR2                | 0.226 (0.137–0.372) | <0.001  | 1.395 (0.773–2.517)  | 0.269   |
| TC                  | 1.763 (1.3–2.392)   | <0.001  | 0.700 (0.424–1.155)  | 0.162   |
| Albumin             | 1.398 (1.264–1.546) | <0.001  | 0.685 (0.576–0.814)  | <0.001  |

Leukocyte1, admission leukocyte count; Leukocyte2, follow-up leukocyte count; NLR, neutrophil–lymphocyte ratio; TC, total cholesterol.

TABLE 4 Comparisons of laboratory and clinical characteristics between admission and follow-up period in patients with epilepsy.

| Parameters                        | Admission (within 24 h) | Follow-up (5–14 days) | P value |
|-----------------------------------|-------------------------|------------------------|---------|
| Leukocyte (*10^9/L)               | 9.25 (6.81–13.10)       | 6.50 (3.51–7.71)       | <0.001  |
| Neutrophil (*10^9/L)              | 6.64 (4.23–9.84)        | 4.11 (2.86–5.07)       | <0.001  |
| Lymphocyte (*10^9/L)              | 1.47 (0.96–2.04)        | 1.54 (1.21–1.99)       | 0.201   |
| NLR                               | 4.41 (2.42–8.65)        | 2.40 (1.79–3.44)       | <0.001  |
| The follow-up seizure attacks     |                         |                        |         |
| Recurrent seizures                | –                       | 33 (28.7%)             | –       |
| No seizures                       | –                       | 82 (71.3%)             | –       |
| Classification of epilepsy        |                         |                        |         |
| Newly diagnosed                   | 56 (48.7%)              | 56 (48.7%)             | –       |
| Chronic epilepsy                  | 59 (51.3%)              | 59 (51.3%)             | –       |
| Brain MRI                         |                         |                        |         |
| Abnormal                          | 68 (59.1%)              | 68 (59.1%)             | –       |
| Normal                            | 47 (40.9%)              | 47 (40.9%)             | –       |
| Anti-seizure drugs                |                         |                        |         |
| Yes                               | 48 (41.7%)              | 48 (41.7%)             | –       |
| No                                | 67 (58.3%)              | 67 (58.3%)             | –       |
| Type of epilepsy                  |                         |                        |         |
| Self–limited seizures             | 64 (55.7%)              | 64 (55.7%)             | –       |
| Status epilepticus                | 51 (44.3%)              | 51 (44.3%)             | –       |

NLR, neutrophil–lymphocyte ratio.
were significantly higher within 24 h of acute seizure compared with the follow-up period of 5–14 days after admission (Table 4).

### Analyses of possible predictors of recurrent seizure attacks after admission

During the follow-up period of 5–14 days after admission, 33 patients had recurrent seizures before NLR2 level were obtained, and 82 patients had no recurrent seizures (Table 4). Univariate analysis used to identify factors influencing the recurrent seizures after admission showed that higher level of NLR1 and status epilepticus were both associated with the recurrent seizures after admission (Table 5). Furthermore, multivariate logistic regression analysis indicated that NLR1 level was an independent predictor of following recurrent seizures after severe epileptic seizure attacks (OR = 1.144, P = 0.002) (Table 6). We further investigated the predictive value of NLR1 for recurrent seizures in these patients after acute seizures. ROC analysis of NLR1 level showed that the best cut-off value was 5.56, AUC was 0.717 (95% CI: 0.611–0.823, P < 0.001), and the sensitivity and specificity were 73 and 71% respectively (Figure 1), indicating that the level of NLR1 could predict the risk of recurrent seizures after admission.

**The correlation between NLR1 and NLR2 in PWE**

Sixteen out of 115 patients (13.9%) had focal seizures and 9 of the 16 patients also had secondary bilateral tonic-clonic seizures. Ninety nine out of 115 (86.1%) had generalized seizures. Out of the 115 patients, 56 had newly diagnosed epilepsy and 59 had chronic epilepsy. Abnormal brain MRI was found in 68 patients and normal brain MRI found in 47 patients. Fifty one patients were admitted because of SE and the remaining 64 patients admitted because of self-limited seizures. Before admission, 48 patients were on treatment with ASDs and the others were not on treatment with ASDs. Regarding to the NLR levels measured within 24h of acute seizure and during the follow-up period of 5–14 days after admission, no difference was found in NLR level between newly diagnosed epilepsy and chronic epilepsy (NLR1: P = 0.546, NLR2: P = 0.474) (Figure 2A, Table 4). Also, no significant difference in NLR level was found between patients with and without abnormal brain MRI (NLR1: P = 0.712, NLR2: P = 0.833) (Figure 2B, Table 4). To investigate the effect of different focal lesions on the level of NLR, 68 patients with abnormal brain MRI were divided into subgroups secondary to cerebrovascular disease (CD) (31 cases), traumatic brain injury (TBI) (14 cases), hippocampal sclerosis (HS) (6 cases), focal cortical dysplasia (FCD) (5 cases), and subgroup secondary to other abnormalities (12 cases). No significant difference in NLR level was found among the five categories of patients with focal seizures (NLR1: P = 0.368, NLR2: P = 0.536) (Figure 2C). As for the treatment with ASDs before admission, 26 cases were treated with monotherapy and 22 treated with combined drugs. As for types of ASDs, sodium valproate was used in 25 cases, carbamazepine in 12

| TABLE 5 | Comparison of baseline characteristics between patients with and without following recurrent seizures after admission. |
|---------|------------------------------------------------------------------------------------------------------------------|
|         | Patients with following recurrent seizures (n = 33) | Patients without following recurrent seizures (n = 82) | P value |
| Gender (men) | 21 | 46 | 0.458 |
| Age (year) | 45.27 ± 17.15 | 45.33 ± 17.60 | 0.988 |
| Leukocyte (1*10^9/L) | 10.04(7.20–13.71) | 8.49(6.19–12.07) | 0.101 |
| NLR1 | 8.01(3.77–14.42) | 3.72(2.07–6.70) | 0.000 |
| SBP (mmHg) | 126.24 ± 18.25 | 126.15 ± 22.86 | 0.670 |
| DBP (mmHg) | 78.03 ± 14.32 | 77.68 ± 14.54 | 0.601 |
| Albumin (g/L) | 41.20(35.15–43.80) | 40.80(35.63–44.10) | 0.819 |
| TG (mmol/L) | 1.22(0.84–1.62) | 1.00(0.78–1.39) | 0.131 |
| TC (mmol/L) | 4.31(3.54–5.08) | 3.85(3.52–4.59) | 0.246 |
| NHS3 | 11.97 ± 4.03 | 10.82 ± 3.61 | 0.137 |
| Chronic epilepsy | 15 | 44 | 0.426 |
| Abnormal brain MRI | 20 | 48 | 0.838 |
| SE | 20 | 31 | 0.026 |
| ASDs taken | 14 | 34 | 0.925 |
| Disease duration (≥5 years) | 10 | 13 | 0.080 |

Leukocyte, admission leukocyte count; NLR, neutrophil–lymphocyte ratio; SBP, systolic blood pressure; DBP, diastolic blood pressure; TG, triglyceride; TC, total cholesterol; SE, status epilepticus.

| TABLE 6 | Univariate and multivariate logistic analyses of possible predictors for the following recurrent seizure attacks after admission. |
|---------|------------------------------------------------------------------------------------------------------------------|
|         | Crude OR (95% CI) | P value | Adjusted OR (95% CI) | P value |
| NLR1 | 1.156(1.066–1.253) | 0.000 | 1.144(1.053–1.243) | 0.002 |
| SE | 2.531(1.105–5.797) | 0.028 | 0.523(0.216–1.266) | 0.151 |

NLR, neutrophil–lymphocyte ratio; SE, status epilepticus.
cases, levetiracetam in 10 cases, lamotrigine in 9 cases, and other ASDs including phenobarbital, topiramate and etc. in the remaining cases. With regard to NLR1 level, no difference was found between patients who received treatment with ASDs and patients who did not (P = 0.370). But, for NLR2 level, it was significantly lower in patients who received treatment with ASDs (Figure 2D, Table 4) than that in patients did not (P = 0.011). Finally, NLR1 level was found significantly higher (Figure 2E, Table 4) in patients admitted because of SE than that in patients admitted because of self-limited seizures (P = 0.013), but no difference of NLR2 levels was found between these two groups of patients (P = 0.290) (Figure 2E, Table 4).

The correlations between NLR level and seizure severity

Seizure severity was assessed by NHS3 scale scores in this study. To evaluate the correlation between NLR level and seizure severity, we found that NLR level was positively correlated with NHS3 scores at admission and during follow-up (Spearman’s correlation r = 0.441, P < 0.001, and r = 0.221, P = 0.009, respectively) (Figures 3A, B).

Discussions

In this retrospective study, 115 patients included were all hospitalized because of acute seizures. Among the 115 patients, 51 patients (44.3%) were admitted because of SE and 56 admitted because of newly diagnosed epilepsy. Forty eight patients were accepting treatment with ASDs before admission. The type of seizures was mainly generalized tonic-clonic seizures.

Studies have indicated an involvement of leukocyte in the pathophysiology of epilepsy (16, 29, 30). The function of peripheral immune cell subsets is altered during epileptic seizures, such as upregulation of CD14-expressed granulocytes and monocytes reduction of HLA-DR-expressed monocytes after seizures (30), and this monocyte infiltration may lead to the recurrence of epileptic seizures (31). On the other hand, a significant increase in the number of blood leukocytes after seizures has been reported in patients with generalized or focal onset seizures, with peripheral blood leukocyte counts above the upper limit of normal in approximately one-third of patients after generalized onset seizures (16, 32). In this retrospective cohort study, we demonstrated that, compared to healthy controls, PWE had higher levels of leukocyte and NLR at admission within 24 h of acute seizure and during the follow-up period. Furthermore, multivariate logistic regression analysis illustrated that the levels of admission leukocyte and NLR were both independently associated with acute epileptic seizures. This indicated that inflammation reflected by NLR was involved in the pathophysiology of epilepsy. It is reported that serum albumin can extravasate from blood vessel into the brain parenchyma when the blood-brain barrier is dysfunctional, and this has been suggested to be involved in the pathogenesis of various types of epilepsy (33–35). In this study, we found that low serum albumin was associated with acute seizures, which effectively confirmed albumin extravasation after acute seizures.

Meanwhile, NLR1 level was found to be a significant predictor for recurrent epileptic seizures after admission in this study. According to the ROC analysis for NLR1, we found that the best cut-off value was 5.56 and the AUC was 0.717 (95% CI: 0.611–0.823, P < 0.001) with a specificity of 73% and a sensitivity of 71%. This finding suggested that an elevated NLR shortly after an acute seizure may predict a tendency for recurrent seizures in the following days, which indicates that the inflammation reflected by NLR may play a causative role in epileptogenesis. Multiple studies have shown that there is a reciprocal interaction between inflammation and epilepsy (9, 10, 13). Epileptic seizures can disrupt the blood-brain barrier and activate a variety of cells including microglia, astrocytes, mononuclear macrophages and neutrophil in the CNS. Subsequently, the activated microglia, reactive astrocytes and infiltrating immune cells release large amounts of pro-inflammatory mediators including IL-6, IL-1β, TNF-α, COX-2, HMGB1 and chemokines, inducing neuroinflammation through multiple signaling pathways. And the neuroinflammation can further increase excitability of the CNS, along with serum albumin extravasation (14, 35, 36). Thus, neuroinflammation can aggravate the severity, duration, and frequency of epileptic seizures and even lead to new-onset seizures (13, 15, 37). On the other hand, patients with systemic autoimmune diseases, including systemic lupus erythematosus (SLE) and Hashimoto’s
Neither NLR1 nor NLR2 level was different between patients with newly diagnosed epilepsy and those with chronic epilepsy (A). There was no significant difference in NLR level between patients with idiopathic epilepsy and those with secondary epilepsy (B), and there was no significant difference in NLR level among the five categories of patients with focal epilepsy (C). NLR2 level in patients on treatment with ASDs was lower than those in patients on no treatment with ASDs (D). NLR1 level in patients with SE was higher than that in patients with self-limited seizures (E). Group comparison was done by Mann–Whitney U test. *P < 0.05.

Group comparison was done by Mann–Whitney U test. *P < 0.05.

thyroiditis, especially children have a significantly increased risk of epilepsy (38). These results suggest that epilepsy is associated with systemic inflammation that can lead to abnormal neuronal connection and neuronal hyperexcitability, thereby mediating the development of epilepsy (10, 17).

In this study, we also found that NLR and leukocyte levels were higher within 24 h of acute seizure than during the follow-up period of 5–14 days after admission. Consistent with previous studies, the increase in NLR level induced by acute seizures subsequently decreased (24), but NLR level remained higher than normal controls during the follow-up period of 5–14 days after admission. From the literature review, most of the previous studies concerning the relationship between epilepsy and NLR were conducted during the acute and subacute stages of seizures, with a maximum follow-up time of 96 h (23, 24). This study is the first to investigate temporal changes in NLR levels during a follow-up period of 5–14 days after an acute epileptic seizure. We found that systemic inflammatory responses reflected by NLR remained increased during 5–14 days of follow-up after acute seizures compared with healthy controls. Some studies have also found that NLR level is higher in patients with chronic temporal lobe epilepsy than in healthy controls (39). Accordingly, it is suggested that the long-lasting systemic inflammatory response induced by acute seizures may be involved in the process of epileptogenesis either in the acute stages or in the chronic stages.

Our study found that there was no difference in NLR levels between the group of patients with newly diagnosed epilepsy and the group of patients with chronic epilepsy, nor between the group of patients with normal brain MRI and the group of patients with focal seizures caused by CD, TBI, HS, FCD and other lesions. This may indicate that the seizure-induced inflammatory response reflected by blood NLR levels is similar in different epileptic causative conditions. Whereas, it should be noted that several studies have shown that the levels of inflammatory cytokines vary with the etiology and historical duration of epilepsy (11, 40). The reason for this inconsistency may be the different inclusion criteria of our study subjects,
or the different of our study to reflect inflammatory emergency response compared with literature reports. Thus, our results suggest that, at least in part, NLR levels depend neither on the simple cumulative effect of recurrent seizures nor on the etiology of epilepsy.

In this study, most patients were already on treatment with ASDs before admission, which mainly included valproic acid, lamotrigine, levetiracetam and carbamazepine. We found that NLR2 level, i.e., NLR level during the follow-up period of 5–14 days after admission, was lower in patients on medications with ASDs than that in patients not on medications with ASDs. On the other hand, previous studies had demonstrated the anti-inflammatory effects of ASDs in epilepsy treatment (41–44). Therefore, we speculate that ASDs may effectively promote the return of NLR to baseline, thereby facilitating the recovery of acute seizure-induced inflammation.

SE is an acute and potentially life-threatening emergency with high morbidity and mortality (45). Proinflammatory events in the periphery or brain have been shown to govern SE occurrence, and SE-induced neurological dysfunction and even death are significantly associated with SE duration (37, 46). In this study, we found that NLR1 level was higher in patients admitted with SE than that in patients admitted with self-limited seizures, implicating that SE induces more severe inflammatory response compared with self-limited seizures. This is consistent with a report that half of the patients developed systemic inflammatory response syndrome (SIRS) after SE, which is considered to be an independent risk factor for drug resistance and death (47). Therefore, routine inflammation assessment, especially NLR assessment, should be performed in SE patients to assess the prognosis of epilepsy and intervene as early as possible.

For patients with uncontrolled epilepsy, seizure severity may be more important than seizure frequency (48). The severity of epilepsy can be assessed by various scales in clinical practice. In this study, NHS3, a valid and easy-to-apply measure, was used to quantitatively assess epilepsy severity (27, 28). We found a significant correlation between NLR levels and NHS3 scores not only within 24 h of acute seizure but also during the follow-up period of 5–14 days after admission. Our study is the first to demonstrate a correlation between NLR level and epilepsy severity, suggesting that NLR is a biomarker for seizure severity. Patients with epilepsy often experience recurrent seizures and generalized tonic-clonic seizures greatly increase the risk of SUDEP depending on the severity of epilepsy (6, 49). Together with the findings that NLR1 level was independently associated with acute seizures and an elevated NLR shortly after an acute seizure may predict a tendency of recurrent seizures in the following days, we believe that monitoring of NLR level can help to assess the severity of acute attacks, so as to identify patients at high risk for developing subsequent seizures and implement effective interventions early to reduce morbidity and mortality.

This study has the following limitations. First, because of its retrospective design, a large number of patients without NLR data were excluded. Second, we recorded NLR2 from a single measure over 5–14 days because the sample size was not large enough. The dynamic changes of neutrophils, lymphocytes and NLR levels can be evaluated more accurately with a larger sample size in the future.

Conclusions

In conclusion, we found that epileptic seizures were associated with inflammatory responses reflected by leukocyte and NLR levels. NLR1 level was independently associated with acute epileptic seizures. Meanwhile, NLR1 level was an important predictor of seizure recurrence after admission. Therefore, NLR-reflected inflammatory responses is a consequence of seizures and may also be responsible for the development of epilepsy. Furthermore, NLR1 and NLR2 levels were respectively associated with SE and use of ASDs, and there was a positive correlation between NLR level and seizure severity, indicating that NLR may be used as a biomarker for seizure severity. We suggest that monitoring of NLR levels should be performed as early as possible to help predict the risk of seizure recurrence following acute epileptic seizure attack and intervene as early as possible.

Data availability statement

The original contributions presented in the study are included in the article/supplementary material, further inquiries can be directed to the corresponding authors.

Ethics statement

The studies involving human participants were reviewed and approved by Ethics Committee of The First Affiliated Hospital of Anhui Medical University. Written informed consent from the participants’ legal guardian/next of kin was not required to participate in this study in accordance with the National Legislation and the Institutional Requirements.

Author contributions

HL explained the data and wrote the paper. YY, MH, and XC acquired and analyzed data. CD, QS, and RLi performed the literature search and data collection. RLiu and XX contributed data curation and investigation. HL and YW designed the
study and revised the manuscript. All authors approved the final manuscript.

Funding

This study was financially supported by the National Natural Science Foundation of China (YW, Grant No. 82071460).

Acknowledgments

We acknowledge the support from the Department of Neurology and the Department of Health Management Center, The First Affiliated Hospital of Anhui Medical University, Hefei, China.

References

1. Fisher RS, Acevedo C, Arzimanoglou A, Bogacz A, Cross JH, Elger CE, et al. Iale of official report: a practical clinical definition of epilepsy. Epilepsia. (2014) 55:475–82. doi: 10.1111/epi.12550
2. Kaddumukasa M, Mugyenyi L, Lhatoo S, Sewankambo N, Blicen X, Sajatovic M, et al. Seizure severity is associated with poor quality of life in people living with epilepsy (PlWe) in Uganda: a cross-sectional study. Epilepsy Behav. (2019) 96:104–8. doi: 10.1016/j.yebeh.2019.04.033
3. Bank AM, Bazil CW. Emergency management of epilepsy and seizures. Semin Neurol. (2019) 39:73–81. doi: 10.1055/s-0038-1677088
4. Hesdorffer DC, Benn EE, Cascino GD, Hauser WA. Is a first symptomatic seizure epilepsy? mortality and risk for recurrent seizure. Epilepsia. (2009) 50:1102–2. doi: 10.1111/j.1528-1157.2008.01945.x
5. Granbichler CA, Zimmermann G, Oberaigner W, Kuchukhidze G, Ndasysaba JP, Taylor A, et al. Potential years lost and life expectancy in adults with newly diagnosed epilepsy. Epilepsia. (2017) 58:1939–45. doi: 10.1111/epi.13902
6. Beghi E. The epidemiology of epilepsy. Neuroepidemiology. (2020) 54:185–91. doi: 10.1159/000503831
7. Salanova V, Sperling MR, Gross RE, Irwin CP, Vollhager JA, Giftakis JE, et al. The saté study at 10 years of follow-up: effectiveness, safety, and sudden unexpected death in epilepsy. Epilepsia. (2021) 62:1306–17. doi: 10.1111/epi.16895
8. Ochoa-Urrea M, Lacuey N, Vilella L, Zhu L, Jamal-Omidi S, Rani MRS, et al. Seizure clusters, seizure severity markers, and sudden death risk. Front Neurosci. (2021) 12:634916. doi: 10.3389/fnneu.2021.634916
9. Terrone G, Salamone A, Vezzani A. Inflammation and epilepsy: preclinical findings and potential clinical translation. Curr Pharm Des. (2017) 23:5569–76. doi: 10.2174/1381612823666170926113754
10. Vezzani A, French J, Bartz T, Baram TZ. The role of inflammation in epilepsy. Nat Rev Neurol. (2011) 7:31–40. doi: 10.1038/nrneurol.2010.178
11. Ma H, Lin H. Advances Regarding neuroinflammation biomarkers with noninvasive techniques in epilepsy. Behav Neurol. (2021) 2021:7946252. doi: 10.1155/2021/7946252
12. Dupuis N, Aurin S. Inflammation and epilepsy in the developing brain: clinical and experimental evidence. CNS Neurol Ther. (2015) 21:141–51. doi: 10.1111/cns.12371
13. Dey A, Kang X, Qiu J, Du Y, Jiang J. Anti-Inflammatory small molecules to treat seizures and epilepsy: from bench to bedside. Trends Pharmacol Sci. (2016) 37:463–84. doi: 10.1016/j.tips.2016.03.001
14. Galic MA, Ruzi K, Pittman QJ. Cytokines and brain excitability. Front Neuroendocrinol. (2012) 33:116–25. doi: 10.1016/j.yfrne.2011.12.002
15. Rana A, Musto AE. The role of inflammation in the development of epilepsy. J Neuroinflammation. (2018) 15:144. doi: 10.1186/s12974-018-1192-7
16. Shah AK, Shein N, Fuerst D, Yangoal R, Shah J, Watson C. Peripheral Wbc count and serum prolactin level in various seizure types and nonepileptic events. Epilepsia. (2001) 42:1472–7. doi: 10.1046/j.1528-1157.2001.11901.x
17. Marchi N, Granata T, Janigro D. Inflammatory pathways of seizure disorders. Trends Neurosci. (2014) 37:55–65. doi: 10.1016/j.tins.2013.11.002
18. Marchi N, Granata T, Freri E, Ciusani E, Ragona F, Puvvuna V, et al. Efficacy of anti-inflammatory therapy in a model of acute seizures and in a population of pediatric drug resistant epilepsy. PLoS ONE. (2011) 6:e18208. doi: 10.1371/journal.pone.0018208
19. Gudon AM, Guldani G, Kone G, Baradaran H, Merkler AE, Mangat HS, et al. Neutrophil-Lymphocyte ratio and perinatal edema growth in intracerebral hemorrhage. Stroke. (2017) 48:2589–92. doi: 10.1161/STROKEAHA.117.018120
20. Lee M, Lim JS, Kim CH, Lee SH, Kim YH, Lim E, et al. High neutrophil-lymphocyte ratio predicts post-stroke cognitive impairment in acute ischemic stroke patients. Front Neurol. (2021) 12:693938. doi: 10.3389/fneur.2021.693938
21. Aly M, Abdalla RN, Bara A, Shaibani A, Hurley MC, Fahrosi BS, et al. Follow-up neutrophil-lymphocyte ratio after stroke thromboembacy is an independent biomarker of clinical outcome. J Neurol Neurosurg Psychiatry. (2021) 13:609–13. doi: 10.1136/jnnp-2020-036342
22. Kesa SP, Altnam B, Usal A. Investigation of the peripheral inflammation (neutrophil-lymphocyte ratio) in two neurodegenerative diseases of the central nervous system. Neurol Sci. (2022) 43:1799–807. doi: 10.1007/s10072-021-05575-7
23. Ozdemir HH, Akk E, Acar A, Tamam Y, Varol S, Cevik MU, et al. Changes in serum albumin levels and neutrophil-lymphocyte ratio in patients with convulsive status epilepticus. Int J Neurosci. (2012) 127:417–20. doi: 10.1080/00207454.2011.1187606
24. Gunes M, Buyukgoz H. Relationship between generalized epileptic seizure and neutrophil-lymphocyte ratio, platelet-lymphocyte ratio, and neutrophil-mediated inflammation. Int J Neurosci. (2020) 130:1095–100. doi: 10.1080/00207454.2020.1722962
25. Scheffer IE, Berkovic S, Capovilla G, Connolly MB, French J, Guilhot L, et al. Iale classification of the epilepsies: position paper of the iale commission for classification and terminology. Epilepsia. (2017) 58:512–21. doi: 10.1111/epi.13799
26. Brodie MJ, Barry SJ, Bamagous GA, Norrie JD, Kwan P. Patterns of treatment response in newly diagnosed epilepsy. Neurology. (2012) 78:1348–54. doi: 10.1212/WNL.0b013e3182563b19
27. Cramer JA, French J. Quantitative assessment of seizure severity for clinical trials: a review of approaches to seizure components. Epilepsia. (2001) 42:119–29. doi: 10.1046/j.1528-1157.2001.19400.x
28. O’Donoghue MF, Duncan JS, Sander JW. The national hospital seizure severity scale: a further development of the chalfont seizure severity scale. Epilepsia. (1996) 37:563–71. doi: 10.1111/j.1528-1157.1996.b00610.x
29. Fabene PF, Navarro Mora G, Martinello M, Rossi B, Merigo E, Ottoboni L, et al. A role for leukocyte-endothelial adhesion mechanisms in epilepsy. Nat Med. (2008) 14:1377–83. doi: 10.1038/nm.1878

30. Ruhnau J, Tennigkeit J, Creasy S, Koppe C, Muszlewski M, Grothe S, et al. Immune alterations following neurological disorders: a comparison of stroke and seizures. Front Neurol. (2020) 11:425. doi: 10.3389/fneur.2020.00425

31. Feng L, Murugan M, Bosco DB, Liu Y, Peng J, Worrell GA, et al. Microglial proliferation and monocyte infiltration contribute to microgliosis following status epilepticus. Glia. (2019) 67:1434–48. doi: 10.1002/glia.23616

32. Morkavuk G, Koc G, Leventoglu A. Is the Differential diagnosis of epilepsy and psychogenic nonepileptic seizures possible by assessing the neutrophil/lymphocyte ratio? Epilepsy Behav. (2021) 116:107736. doi: 10.1016/j.yebeh.2020.107736

33. Marchi N, Teng Q, Ghosh C, Fan Q, Nguyen MT, Desai NK, et al. Blood-brain barrier damage, but not parenchymal white blood cells, is a hallmark of seizure activity. Brain Res. (2010) 1353:176–86. doi: 10.1016/j.brainres.2010.06.051

34. Marchi N, Johnson AJ, Puvenna V, Johnson HL, Tierney W, Ghosh C, et al. Modulation of peripheral cytotoxic cells and icetogenesis in a model of seizures. Epilepsia. (2011) 52:3627–34. doi: 10.1111/j.1528-1167.2011.03080.x

35. Librizzi L, Vila Verde D, Colciaghi F, Deleo F, Regondi MC, Costanza M, et al. Peripheral blood mononuclear cell activation sustains seizure activity. Epilepsia. (2021) 62:1715–28. doi: 10.1111/epi.16935

36. Iori V, Frigerio F, Vezzani A. Modulation of neuronal excitability by immune mediators in epilepsy. Curr Opin Pharmacol. (2016) 26:118–23. doi: 10.1016/j.coph.2015.11.002

37. Wang M, Chen Y. Inflammation: a network in the pathogenesis of status epilepticus. Front Mol Neurosci. (2018) 13:341. doi: 10.3389/fnmol.2018.00341

38. Ong MS, Kohane IS, Cai T, Gorman MP, Mandl KD. Population-Level evidence for an autoimmune etiology of epilepsy. JAMA Neurol. (2014) 71:569–74. doi: 10.1001/jamaneurol.2014.188

39. Simoes PSR, Zanelatto AO, Assis MC, Varella PPV, Yacubian EM, Carrete H, et al. Plasma kallikrein-kinin system contributes to peripheral inflammation in temporal lobe epilepsy. J Neurochem. (2019) 150:296–311. doi: 10.1111/jnc.14793

40. Choi J, Kim SY, Kim H, Lim BC, Hwang H, Chae JH, et al. Serum alpha-synuclein and IL-1beta are increased and correlated with measures of disease severity in children with epilepsy: potential prognostic biomarkers? BMC Neurol. (2020) 20:85. doi: 10.1186/s12883-020-01662-y

41. Gibbons HM, Smith AM, Teoh HH, Bergin PM, Mee EW, Faull RL, et al. Valproic acid induces microglial dysfunction, not apoptosis, in human glial cultures. Neurobiol Dis. (2011) 41:96–103. doi: 10.1016/j.nbd.2010.08.024

42. Haghikia A, Ladage K, Hinkerohe D, Vollmar P, Heupel K, Dermitzel R, et al. Implications of antiinflammatory properties of the anticonvulsant drug levetiracetam in astrocytes. J Neurosci Res. (2008) 86:1781–8. doi: 10.1002/jnr.21639

43. Wang CH, Hisao CJ, Lin YN, Wu JW, Kuo YC, Lee CK, et al. Carbamazepine attenuates inducible nitric oxide synthase expression through akt inhibition in activated microglial cells. Pharm Biol. (2014) 52:1451–9. doi: 10.3109/13880209.2014.898074

44. Abu-Rish EY, Dahabiyeh LA, Bustanji Y, Mohamed YS, Browning MJ. Effect of lamotrigine on in vivo and in vitro cytokine secretion in murine model of inflammation. J Neuroimmunol. (2018) 322:36–45. doi: 10.1016/j.jneuroim.2018.06.008

45. Unterberger I. Status epilepticus: do treatment guidelines make sense? J Clin Neurophysiol. (2016) 33:10–3. doi: 10.1097/WNP.0000000000000222

46. Janigo D, Illland PH. 2nd, Marchi N, Granata T. A role for inflammation in status epilepticus is revealed by a review of current therapeutic approaches. Epilepsia. (2013) 54 Suppl 2:S60–2. doi: 10.1111/epi.12271

47. Szklener S, Korchut A, Godek M, Balicka-Adamik L, Bielecki D, Rejdak R, et al. Systemic inflammatory response syndrome in the course of status epilepticus: 7-year, two-center observational study. Epilepsy Res. (2017) 137:53–5. doi: 10.1016/j.eplepsres.2017.09.003

48. Borgha S, Tomaszewski EL, Halling K, de la Loge C. Understanding the patient perspective of seizure severity in epilepsy: development of a conceptual model. Patient. (2016) 9:419–31. doi: 10.1007/s40271-016-0165-0

49. Shorvon S, Tomson T. Sudden unexpected death in epilepsy. Lancet. (2011) 378:2028–38. doi: 10.1016/S0140-6736(11)60176-1